Azapropazone--a treatment for hyperuricaemia and gout?
In a metabolic ward study of five patients, azapropazone lowered plasma uric acid but exerted only a modest and variable uricosuric effect without altering urinary xanthine and hypoxanthine levels. An alternative mechanism other than uricosuria or xanthine oxidase inhibition must account for some of the hypouricaemic action of this drug. During the first day of treatment urine volume and pH declined sharply. In a separate investigation, 22 patients were given azapropazone and 18 were given allopurinol combined with colchicine for 3 months. Allopurinol reduced plasma uric acid more quickly but at the end of the study there was little difference in the hypouricaemic results achieved by both drugs. Recurrent gout occurred more frequently with allopurinol but side-effects were confined to those taking azapropazone. A slight rise in blood urea and creatinine and a fall in haemoglobin were also features of long-term azapropazone treatment.
D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use; D001032:Apazone / Q000627:therapeutic use*; D003404:Creatinine / Q000652:urine; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009994:Osmolar Concentration; D014227:Triazines / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood* / Q000652:urine; D014554:Urination / Q000187:drug effects
D014227:Triazines; D014527:Uric Acid; D000493:Allopurinol; D003404:Creatinine; D001032:Apazone